chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Inflammation with induration right thigh. Rx Benadryl tsp po BID.
Patient complained of feeling like "tiny spiders were crawling all over his arms, face and some of his leg" and complained of headache.
Pt was given 1.0  mL of vaccine rather than .5 mL.
The day after receiving her 1st dose of the Pfizer COVID vaccine on 6/11/21 patient reports having flue like symptoms, throwing up, body ache, diarrhea, but denies a fever. These common side effects did not resolve and got worse. On 7/1/21 patient says she was feeling over heated and hot, was vomiting and even lost consciousness (passed out). On 7/2/21 she got her second dose of the Pfizer vaccine and her side effects have continued. She passed out again and was hospitalized from 7/13/21 to 7/14/21. As of today patient reports vomiting and dry heaving has continued and overheating.
1st Covid 19 vaccine Pfizer: sore arm 4/1/21 5pm-10am of 4/2/21. Upset elimination tract 4/1/21 10pm-5am of 4/2/21. Headache 4/1/21 8pm-4/2/21 6pm.
This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 52 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 30Aug2021 18:15 (Lot number: FC3189) at the age of 52 years as dose 1, single for Covid-19 immunisation. Relevant medical history included: "High blood pressure" (unspecified if ongoing), notes: Other medical history: High blood pressure. Concomitant medication(s) included: ENALAPRILAT taken for hypertension. The following information was reported: EPISTAXIS (non-serious) with onset 31Aug2021 21:00, outcome "not recovered", described as "I had a massive nosebleed. I continue to experience small nose bleeds thereafter". Therapeutic measures were not taken as a result of epistaxis. Additional information: The patient was not pregnant at vaccination. Facility type vaccine was Pharmacy or Drug Store. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient received other medications within 2 weeks of vaccination was ENALAPRILAT. The patient did not have Known allergies. Patient had not been diagnosed with COVID-19 prior to vaccination and had not been tested since the vaccination. Clinical course: A little over 24 hours after getting the Pfizer vaccine I had a massive nosebleed. I continue to experience small nose bleeds thereafter. This is not normal for me. This is directly related to the vaccine. No follow-up attempts are possible. No further information is expected.
Ringing/pressure in left ear began within 4 hours of vaccine administration and continues almost 2 weeks later. Some varying degrees of intensity but continuous symptoms.
87y.o. male known to our office for management of CLL/SLL who completed 6 cycles of RminiCHOP on 7/27/2022. Pt was admitted to hospital on 8/3/2022 for SOB, cough, and subjective fevers. Pt was found to be covid19 positive in the ED. CXR with infiltrate vs atelectasis in right midlung and bilateral bases. CTA Chest PE protocol 8/4 negative for PE, showed multifocal areas of consolidation. Pt was started on empiric vanoc/cefepime on admit. ID and pulmonology were consulted. Vanco stopped. Pt remained on Cefepime x 7 days total, completed on 8/10/22. Pt was also treated with remdesivir 8/5/2022-8/8/22, and started on Decadon 6mg daily x 10 days. Pt will complete last two days as OP, course will complete on 8/13/22. Pt will also remain on PPI ppx x 1 week at discharge. Pt was neutropenic on admit. He received Neulasta on 7/27/2022, Granix started on admission due to persistent neutropenia and acute infection. Discontinued Granix 8/5 given ANC >1.0. Patient was able to be weaned back to room air on 8/11/22. PT/OT evaluated patient and recommended SAR at discharge. Patient's wife was very adamant that patient was discharged home with home care. Patient became very weak during hospitalization and requires two person assist to stand. His wife remained insistent patient be discharged to her care. Exception made to have wife come to hospital while patient in isolation so she was able to visualize patient and better understand recommendations for SAR. Wife submitted written documentation that she understands the risks of being patient home and prefers patient be discharged to her care with home care. Patient has two son's that are also available to help patient as needed. After long deliberation with patient's wife, will agreed to have patient discharged with home skilled nursing, PT, and OT. Patient's wife is an RN and was well educated on the risk she is taking on by bringing patient home. Patient will follow up in our office in 2 weeks after he is cleared from COVID 19 isolation.
vaccine 1/21/22. face and lips swelling 1/23/22 (>48 hours after vaccination). visited aprn 1/24/22 and received steroid shot and benadryl.
covid: vaccination clinic S: At 1557 patient c/o tongue swelling and itchiness. Given 25mg PO benadryl at 1557   O: Patient alert and oriented, airway patent.   BP 129/88 HR 74 O2 98%   1617 Repeat O2 sat 98% HR 59. Patient c/o persistent tongue swelling.    A/P: 28 F with history of nut allergy with tongue swelling after Pfizer vaccine. EMS notified 1620. Patient evaluated by EMS and declined further treatment by EMS and stated that she would walk over to ED for further evaluation.    Further return to ED precautions discussed with patient.
numbness; cramping in her legs; heaviness in her legs; feels a pinch sensation; This is a spontaneous report from a contactable consumer (Patient). A 57-year-old female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Batch/Lot number: not reported) via an unspecified route of administration on 21Jul2021 (at the age of 56 years old) as DOSE 2, Single for covid-19 immunisation. The patient medical history and concomitant medications was not reported. The patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Batch/Lot number: not reported) via an unspecified route of administration on unspecified date for covid-19 immunisation. On Jul2021 the patient experienced About 6 to 7 days after, consumer experienced numbness and cramping in her legs. consumer didn't think it was the vaccine that caused this because she researched the side effects and what she was experiencing was not listed. She was provided patient information from the pharmacy and is experiencing all the symptoms that were listed on that form. consumer feels a heaviness in her legs like after sitting for too long and sometimes feels a pinch sensation and then it goes away. It is moving around her legs. consumer saw a new allergist yesterday and feels the symptoms have moved to her right arm. The outcome of the event pinch sensation was recovered on unspecified date in 2021 while other events was unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.  Follow-up activities closed. Batch/lot number not available.
Case number PHEH2014US017776 is an initial spontaneous report from the nurse received on 04 Sep 2014. This report refers to a patient of an unknown age and gender. The patient was vaccinated with MENVEO (batch number: not reported) on an unknown date. It was reported that the vaccine which was administered to the patient was exposed to temperatures of down to 30 F since 30 Jul 2014. No adverse event reported following this medication error (incorrect storage of drug).
Moderna Shot on February 23, 2021. Tired, sluggish and headache along with some ringing in the head.  March 22, 2021 I had second Moderna shot. My arm was very swollen, fatigue and bad headache with loud ringing in the head. My blood pressure accelerated  to nearly 200/88 and had to be admitted to the ER three days after shot. I was in the hospital for two days and had a series of CAT scans and ultrasounds.  Loud ringing in my head has not stopped. Never had a history of high blood pressure, but now they put me on high blood pressure medication along with the baby aspirin. I was a relatively healthy woman until I had these vaccinations.
pt recvd vax & pt devel a low grade fever & erythematous rash; no further details were provided;
On Saturday 9/8/18 mom noticed a rash started to develop on the right thigh (tdap) and has been increasing in size and getting worse, currently there is a welt the size of a 1/2 dollar bill and multiple small welts surrounding the area. No fevers. Notified provider, who stated to administer Beandryl, Zyrtec. Told mom if itching to apply calamine lotion. She voiced understanding & will call back if no improvement.
Patient reported chest tightness and warmth starting in her chest and rising upwards to her neck. Also complained of warmth and pain that then spread down her body. Reported weakness in vaccine arm that is still lingering.
pt has recvd vax for past 10 yrs w/o incident;pt recvd flu vax 12OCT  12NM & 14OCT 4-5PM began experiencing lt arm discomfort, lt hip discomfort like bone was breaking, nausea, h/a lt temple, eyes sore, no appetite
This spontaneous report was received from a health care worker (medical assistant) regarding unspecified number of patients of unknown gender and age. The reporter states that on an unknown date the patient's were vaccinated with ROTATEQ (dose, frequency, lot number, expiry date not reported) orally. Also reported that the patient's were administered doses of ROTATEQ that were improperly stored and no adverse events were reported. This is one of the several reports received from the same reporter. Additional information has been requested.
pt stated was in africa & had some rash on both arms @ vax sites;pt arrived home on 23FEB98 & rash was  so bad on both arms started using cortisone cream 0.1% & the rash improved;If pt quits using cream the rash returns;small bumps;pruritic
Presented with large area (about the size of an orange) of redness and swelling around injection sight of where the flu vaccine was injected.
On 03/11/2021 I had a lot of pain in my vulva. I went to see GYN because of the pain. She referred me to a dermatologist who I saw on 03/18/2021, she thought I had Lichen Sclerosus. The dermatologist referred me to gynecologist, who specializes in Lichen Sclerosus. I saw Dr. on 05/03/2021. Lichen Sclerosus is an autoimmune disease which is why I connected to the vaccine. The treatment was laser, an ongoing treatment, I have had 2 of them and I am going to have a 3rd treatment. Dr. prescribed prednisone, clobetasol (cream). 7% of people who have Lichen Sclerosus develop cancer. Lichen Sclerosus can be treated but it does not go away. I would consider it a permanent damage.
patient received the MMR II vaccine as wel as the VARIVAX vaccine on both 10/22/2020 and 10/30/2020; This spontaneous report was received from a nurse practitioner and refers to a female patient of an unknown age. Her medical history, concurrent conditions, concomitant medications, drug reaction or allergies were not provided.  On 22-OCT-2020, the patient came to the clinic with the mother and was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) rHa, lot # S037502, upon internal validation determined as a valid lot #, expiration date was reported and also validated as 20-NOV-2021 (dose, strength were unknown, route of administration and anatomical location were not reported) for prophylaxis.  On the same date, she also received the dose of varicella virus vaccine live (oka/merck) (VARIVAX), lot # T010313, expiration date was reported as 26-MAR-2020 (expired date), but upon internal validation, established as 24-MAR-2022 (dose, strength were unknown, route of administration and anatomical location were not reported) for prophylaxis.  On 30-OCT-2020, 8 days later, the patient came to the clinic with the father, and received the next doses of the same vaccines again, earlier than the recommended interval between doses (inappropriate schedule of product administration). The reporter wanted to ensure, that it was fine for the patient.
intermittent palpitations; thinks that patient developed shingles/suspected shingles; Pustules at V3 Dermatome; This case was reported by a physician and described the occurrence of shingles in a 88-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included cardiovascular disorder.   On 19th August 2021, the patient received the 1st dose of Shingrix. In August 2021, 36 hrs after receiving Shingrix, the patient experienced shingles and pustular rash. On 19th August 2021, the patient experienced palpitation. On 31st August 2021, the outcome of the shingles, pustular rash and palpitation were recovered/resolved.   It was unknown if the reporter considered the shingles, pustular rash and palpitation to be related to Shingrix.  Additional details were provided as follows: The doctor of medicine (MD) reported that the patient received the 1st dose of Shingrix and 36 hours after the vaccination, she developed pustules at V3 dermatome. The patient had intermittent palpitations, no chest pain or shortness of breath noted. The reporter thought that the patient had developed shingles following 1st dose of Shingrix. The reporter consented to follow up.
right lower extremity swelling and redness. He had an outpatient venous duplex of his RLE done earlier in the day and was referred to the ED due to extensive DVT.  Heparin Drip
Redness/swelling below injection site. Tx with intermittent ice, ZYRTEC and ibuprofen PRN.
Rash; Rash was still present and continues to provide discomfort; This is a spontaneous report from a non-contactable consumer, the patient. A non-pregnant female patient of unspecified age received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733), via an unspecified route of administration on 19Apr2021 as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in 2021, the patient experienced a rash which was still present and continued to provide discomfort. Since the vaccination, the patient had not been tested for COVID-19. The events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the events rash and was still present and continued to provide discomfort was not recovered at the time of report.  No follow-up attempts are possible. No further information is expected.
Bruise on the site of injection which is about 4inches long; This spontaneous case was reported by a consumer and describes the occurrence of CONTUSION (Bruise on the site of injection which is about 4inches long) in a 77-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Allergy.    On 23-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 24-Mar-2021, the patient experienced CONTUSION (Bruise on the site of injection which is about 4inches long). At the time of the report, CONTUSION (Bruise on the site of injection which is about 4inches long) had not resolved.            Concomitant medications were reported as allergy medications.
Patient received Pfizer vaccine at approximately 12:00 PM and drove to observation area.  Observer reviewed safety measures with patient. Observer stated that patient c/o tingling at injection site. At approximately 12:05PM observer stated that she saw patient slightly waving paddle and went to assess patient, upon  arrival to patient's car, patient was unresponsive. Emergency measures implemented. Epi administered via IM route, Oxygen applied, vital signs taken and EMS called. Patient remained unresponsive up EMS arrival. Patient was transported to the ER via EMS.
5/4/06 mother presented child to health dept. Developed fine red rash on trunk, arms, legs. Approx 1-2 days ago. States babysitter did launder clothes in different detergent. 5/5/06 rash, worse, saw PCP 5/4/06 now going to ER 5/5/06.
Information has been received from a registered nurse concerning a 13 year old male patient who on an unspecified date was vaccinated with a dose of PROQUAD (Merck) (Lot # not provided), "back to school dose required by the state", instead of VARIVAX (Merck). It was reported that the patient had not experienced any known symptoms. It was unknown if the patient sought medical attention. This is one of several reports received from the same source. Additional information has been requested.
Information has been received from a physician via Company representative concerning to a patient of unknown age and gender. Concurrent and historical conditions were not reported. Concomitant therapies were not provided. On 27-AUG-2015, the patient was vaccinated with an improperly stored dose of GARDASIL (Lot No. K001631, exp. 24-FEB-2017) (dose and site not reported). On an unspecified dates, the GARDASIL vaccine had six temperature excursions: 168, 416, 336, 24, 80, and 1172 hours respectively. The lowest recorded temperatures were 30 (-1.111111111 Celsius degrees) and -3 (-3 Celsius degrees). The highest recorded temperatures were 49 (9.444444444 Celsius degrees), 47 (8.333333333 Celsius degrees), 59 (15 Celsius degrees) and 48 (8.888888889 Celsius degrees). The vaccine status was reported as "in excursion". The vaccine storage criteria and the vaccine excursion were reported as "Refrigerator(R)". No adverse effects were reported. There was no product quality complaint involved. This is one of several reports received from the same reporter. Additional information has been requested.
On 12/16/97, 9 months after immunizations were given, mother reported that child would not walk after last injection for 2 weeks and he saw Dr 3 times. She thought the clinic had contacted me. I had not had any communication with the Dr. or clinic. I called Dr and spoke to his nurse. She read me pt's progress notes. they said nothing about inability to walk. Child was seen by Dr on 3/21/97 and 2 more times. Progress notes stated child had elevated WBC, ear infection and cold. Received Rocephin injections for treatment. Nurse said Dr did consider a possible reaction to  MMR also, but notes are more suggestive of infection as cause. Nurse advised a consult with family physician prior to giving 2nd MMR when it was due. I cannot find a record that I ever filled out a VAER report at that time. Patient was now ready to start kindergarten and Mom brought him in for boosters. She did not mention the previous reaction. I read my notes on child's immune record. I contacted Dr for review of pt's record. He called me back and said he had reviewed the record and consulted with Dr, pediatrician. He said to give pt a 2nd MMR  due to his illness back in 1997. I went ahead and administered the pt's other pre-school boosters, but did not give 2nd MMR. We had noted Dr's orders for no 2nd MMR in his record on SDIIS.
Infanrix on 09/14/2020 (3 months prior to dosing schedule); This case was reported by a nurse via call center representative and described the occurrence of drug dose administration interval too short in a 1-year-old female patient who received DTPa (Infanrix) (batch number 49TM3, expiry date 28th May 2022) for prophylaxis.   Co-suspect products included dtpa vaccine pre-filled syringe device (Infanrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   Previously administered products included Pediarix (1st dose received on an unknown date), Pediarix (2nd dose received on an unknown date) and Pediarix (received 3rd dose on 12th June 2020 from batch 2KD4D with expiry date 8th May 2022).   On 14th September 2020, the patient received Infanrix and Infanrix Pre-Filled Syringe Device. On 14th September 2020, unknown after receiving Infanrix and Infanrix Pre-Filled Syringe Device, the patient experienced drug dose administration interval too short. On an unknown date, the outcome of the drug dose administration interval too short was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The registered nurse reported administration of Infanrix following 3 doses of Pediarix. As per FDA, infanrix can be used to complete DTaP vaccination series initiated with pediarix. The patient received Infanrix vaccine 3 months prior to dosing schedule, which led to drug dose administration interval too short. The reporter consented to follow up. The batch number for Infanrix vaccine was reported as 49PM3 however it was updated as 49TM3 as per sales data sheet. The batch number for Pediarix vaccine was reported as 2K94D however it was updated as 2KD4D as per sales data sheet.
pt c/o arm hurting as lt bldg;passed out on grass beside car before mom could get doors open;c/o h/a & was very sweaty;slept for about 3hr @ home but ate 3 taco's for dinner;MD feels was vasovagal response;
About 90 min post vaccine, my vision became extremely blurry. My heart rate and BP was elevated and remained elevated with any physical activity or exertion. I became "swollen" in the face and arm but did not break out in hives. My BP and pulse remained elevated for 4 days. By day 3, my lymphnodes in my armpit became extremely swollen. I have remained slightly swollen and periodically break out in hives without regular Benadryl and famotidine/cetirizine  doses.
This is being reported because of the incident occurring 2 days after the Moderna Covid-19 vaccination. It was reported that the patient expired on 1/9/21, 2 days after receiving  the Moderna vaccine.  Upon screening of patient prior to  administration on 1/7/21, the patient completed paperwork answering  NO to the following "Do you currently have any active infections or acute respiratory illness or fever."
This spontaneous report as received from a medical assistant refers to a 13 month old patient of unknown gender. The concurrent conditions, drug reactions/allergies and medical history of the patient were not reported. On 07-DEC-2016, the patient was vaccinated with a dose of improperly stored VARIVAX (strength, dose, route of administration, anatomical location, lot number and expiration date were unknown) for prophylaxis, which was stored at 1.1 Celsius degrees (°C) for 27 minutes, 0.7 °C for 19 minutes, 1.1 °C for 36 minutes, 0.7 °C for 29 minutes, 1.3 °C for 17 minutes, 1.1 °C for 20 minutes, 0.9 °C for 26 minutes, 0.7 °C for 31 minutes and 1.2 °C for 24 minutes. There was no previous temperature excursion. Moreover, the temperature excursions were detected by a data logger. No concomitant therapies nor adverse effects were reported. No product quality complaint was involved. This is one of several cases from the same reporter. Additional information has been requested.; Sender's Comments: US-009507513-1701USA007921: US-009507513-1701USA007910: US-009507513-1701USA004148: US-009507513-1701USA003168: Original Case : 1701USA004150 US-009507513-1701USA007912: Original Case : 1701USA007906 US-009507513-1701USA007922: US-009507513-1701USA007881: US-009507513-1701USA007913: US-009507513-1701USA007882: US-009507513-1701USA004150: US-009507513-1701USA007958: US-009507513-1701USA007906: US-009507513-1701USA007895: US-009507513-1701USA007896: US-009507513-1701USA007923: US-009507513-1701USA004152: US-009507513-1701USA007883: US-009507513-1701USA007897: US-009507513-1701USA007905: US-009507513-1701USA007884: US-009507513-1701USA007924: US-009507513-1701USA007925: US-009507513-1701USA007847: US-009507513-1701USA007885: US-009507513-1701USA007909: US-009507513-1701USA007898: US-009507513-1701USA007914: US-009507513-1701USA007915: US-009507513-1701USA007916: US-009507513-1701USA007848: US-009507513-1701USA007849: